好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

MIN102 (Leriglitazone), a Brain Penetrant PPAR Gamma Agonist for the Treatment of Friedreich’s Ataxia
General Neurology
S51 - General Neurology: Models of Clinical Care and Disease (2:24 PM-2:36 PM)
008

Friedreich’s ataxia (FRDA) is a rare autosomal recessive neurodegenerative disease characterized by progressive spinocerebellar and sensory ataxia, cardiomyopathy, diabetes mellitus and skeletal deformities. It is caused by mutations in the frataxin (FXN) gene resulting in reduced levels of frataxin, causing mitochondrial dysfunction, reduced activity of iron-sulphur cluster containing enzymes, mitochondrial iron overload, defective energy production and calcium metabolism, oxidative stress and dysregulation of mitochondrial homeostasis and biogenesis. Several studies have shown that the peroxisome-proliferator activator receptor gamma (PPARγ)/PPARγ coactivator 1 alpha (PGC1α) pathway is dysregulated in frataxin deficiency, contributing to the disease pathogenesis and supporting PPARγ as a potential therapeutic target for FRDA. Leriglitazone is a novel brain penetrant, small molecule, which selectively acts through the PPARγ.

To investigate the preclinical efficacy of a new investigational drug, leriglitazone, in preclinical models of Friedreich´s Ataxia.

Frataxin-depleted primary sensory neurons of the dorsal root ganglia (DRG) and cardiomyocytes, were used to study the effects of leriglitazone on disease-related phenotypes in vitro. FRDA patient fibroblasts and the in vivo knock-in/knock-out (KIKO) mouse model were used to validate the effect of leriglitazone on relevant mitochondrial markers. The transgenic YG8sR mice were applied to assess the effect of leriglitazone on motor function.

The data generated in the different preclinical FRDA related models showed that leriglitazone is efficacious in increasing DRG neurons survival and decreasing neurite degeneration, compensating the alterations on mitochondrial markers such as PGC1α, improving mitochondrial function, restoring energy production and calcium dysregulation, and improving global motor functions.

The preclinical results support the investigation of leriglitazone for the treatment of FRDA. Leriglitazone is currently in clinical phase 2/3 for the treatment of AMN, in phase 2 for cALD and in phase 2 for Friedreich´s Ataxia.

Authors/Disclosures
Sonia Poli
PRESENTER
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
David R. Lynch, MD, PhD (Children's Hospital of Philadelphia) The institution of Dr. Lynch has received research support from reata. The institution of Dr. Lynch has received research support from PTC. Dr. Lynch has received intellectual property interests from a discovery or technology relating to health care.
Marc Martinell Marc Martinell has received personal compensation for serving as an employee of Minoryx Therapeutics. Marc Martinell has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Minoryx Therapeutics. Marc Martinell has stock in Minoryx Therapeutics. Marc Martinell has received intellectual property interests from a discovery or technology relating to health care.
Pilar Pizcueta Pilar Pizcueta has received personal compensation for serving as an employee of Minoryx Therapeutics SL.